304 related articles for article (PubMed ID: 26075588)
1. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
Kao DP; Haigney MC; Mehler PS; Krantz MJ
Addiction; 2015 Sep; 110(9):1468-75. PubMed ID: 26075588
[TBL] [Abstract][Full Text] [Related]
2. Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data.
Kao D; Bucher Bartelson B; Khatri V; Dart R; Mehler PS; Katz D; Krantz MJ
Ann Intern Med; 2013 May; 158(10):735-40. PubMed ID: 23689766
[TBL] [Abstract][Full Text] [Related]
3. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.
Sessler NE; Walker E; Chickballapur H; Kacholakalayil J; Coplan PM
Postgrad Med; 2017 Jan; 129(1):62-68. PubMed ID: 27977317
[TBL] [Abstract][Full Text] [Related]
4. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes.
Krantz MJ; Garcia JA; Mehler PS
Pharmacotherapy; 2005 Apr; 25(4):611-4. PubMed ID: 15977920
[TBL] [Abstract][Full Text] [Related]
5. Corrected QT interval during treatment with methadone and buprenorphine--relation to doses and serum concentrations.
Stallvik M; Nordstrand B; Kristensen Ø; Bathen J; Skogvoll E; Spigset O
Drug Alcohol Depend; 2013 Apr; 129(1-2):88-93. PubMed ID: 23084592
[TBL] [Abstract][Full Text] [Related]
6. Reply to Cataldo (2016): Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
Kao D; Haigney MC; Mehler PS; Krantz M
Addiction; 2016 Sep; 111(9):1686-7. PubMed ID: 27273759
[No Abstract] [Full Text] [Related]
7. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
8. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.
Krantz MJ; Kutinsky IB; Robertson AD; Mehler PS
Pharmacotherapy; 2003 Jun; 23(6):802-5. PubMed ID: 12820821
[TBL] [Abstract][Full Text] [Related]
9. Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes.
Esses JL; Rosman J; Do LT; Schweitzer P; Hanon S
J Interv Card Electrophysiol; 2008 Nov; 23(2):117-9. PubMed ID: 18686025
[TBL] [Abstract][Full Text] [Related]
10. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
11. Ventricular arrhythmias in patients treated with methadone for opioid dependence.
Hanon S; Seewald RM; Yang F; Schweitzer P; Rosman J
J Interv Card Electrophysiol; 2010 Jun; 28(1):19-22. PubMed ID: 20177760
[TBL] [Abstract][Full Text] [Related]
12. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?
Vieweg WV; Hasnain M; Howland RH; Hettema JM; Kogut C; Wood MA; Pandurangi AK
Am J Med; 2012 Sep; 125(9):859-68. PubMed ID: 22748401
[TBL] [Abstract][Full Text] [Related]
13. Torsade de pointes associated with very-high-dose methadone.
Krantz MJ; Lewkowiez L; Hays H; Woodroffe MA; Robertson AD; Mehler PS
Ann Intern Med; 2002 Sep; 137(6):501-4. PubMed ID: 12230351
[TBL] [Abstract][Full Text] [Related]
14. QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
Ryan K; Benz P; Zosel A; Farkas A; Theobald J
Cardiovasc Toxicol; 2022 Sep; 22(9):866-877. PubMed ID: 35930218
[TBL] [Abstract][Full Text] [Related]
15. Torsades de pointes with methadone.
Prescrire Int; 2005 Apr; 14(76):61-2. PubMed ID: 15875343
[TBL] [Abstract][Full Text] [Related]
16. Perioperative torsade de pointes: a systematic review of published case reports.
Johnston J; Pal S; Nagele P
Anesth Analg; 2013 Sep; 117(3):559-564. PubMed ID: 23744954
[TBL] [Abstract][Full Text] [Related]
17. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.
Perrin-Terrin A; Pathak A; Lapeyre-Mestre M
Fundam Clin Pharmacol; 2011 Aug; 25(4):503-10. PubMed ID: 20825488
[TBL] [Abstract][Full Text] [Related]
18. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
19. Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting.
Kao DP; Hiatt WR; Krantz MJ
Pharmacotherapy; 2012 Aug; 32(8):767-71. PubMed ID: 22744806
[TBL] [Abstract][Full Text] [Related]
20. Ventricular Arrhythmias Associated With Over-the-Counter and Recreational Opioids.
Krantz MJ; Rudo TJ; Haigney MCP; Stockbridge N; Kleiman RB; Klein M; Kao DP
J Am Coll Cardiol; 2023 Jun; 81(23):2258-2268. PubMed ID: 37286256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
